Undeniable Deaths After HPV Vaccination

Written by Yuhong Dong, M.D., Ph.D on July 1, 2023. Posted in Current News

The human papillomavirus (HPV) vaccine has been recommended by doctors as the main measure to take against cervical cancer. Many people, including doctors, think there is no risk since there are no recognized cases with proven association with the vaccine

But is this true? Does the HPV vaccine really deliver the stellar protection promised or is it a double-edged sword with risks that outweigh the benefits?

In this series, “The HPV Vaccine: A Double-Edged Sword?” we will provide a collection of documented evidence of death and serious injuries associated with Gardasil.

Their existence is undeniable. We will also analyze the potential mechanisms for serious adverse events and disclose important facts about the vaccine.

We will conclude with a discussion about the underlying root causes for the phenomena behind the HPV vaccines and will provide recommendations for key stakeholders.

With nearly two decades of experience as a medical doctor and a doctorate in infectious disease, I have been dedicated to extensive research, allowing me to acquire profound insights into diverse viruses and vaccines.

I have been actively engaged in numerous clinical research projects, acquiring a wealth of knowledge in assessing the efficacy and safety of pharmaceutical products. My expertise extends beyond laboratory experiments and encompasses a comprehensive understanding of their tangible impact on individuals.

Since taking the sacred Hippocratic oath 32 years ago, which solemnly emphasizes the principle: “First, do no harm,” I have felt a profound sense of responsibility. This responsibility compels me to write about the HPV vaccine, which carries significant implications for the lives of young individuals.

For those who are considering the HPV vaccine, here are my thoughts and recommendations.

HPV Vaccines and CDC Recommendations

There have been three HPV vaccines—the quadrivalent HPV vaccine (Gardasil, 4vHPV, approved in June 2006), the bivalent HPV vaccine (Cervarix, 2vHPV, approved in October 2009), and the 9-valent HPV vaccine (Gardasil 9, 9vHPV, approved in December 2014)—all licensed by the U.S. Food and Drug Administration (FDA).

The HPV virus has over 200 strains. There are 14 high-risk HPV strains that are associated with cervical cancer: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

All three vaccines are protective against HPV types 16 and 18, which are responsible for most HPV-related cancers, according to the Centers for Disease Control and Prevention (CDC). Gardasil 9 contains HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58.

Since Cervarix was withdrawn from the U.S. market in 2016 due to “very low market demand,” the HPV vaccines we focus on in this series are Gardasil and Gardasil 9.

According to the CDC, “HPV vaccine is recommended for routine vaccination at age 11 or 12 years. HPV vaccines can be given starting at age 9.” The HPV vaccination is given as a series of either two or three doses, depending on age at initial vaccination.

Safety Assessment of Vaccines Is Stricter Than for Drugs

When we talk about vaccines, people normally do a risk-benefit analysis. The bar set for the safety of a vaccine is much higher than that for a therapeutic drug.

Drugs are used for patients who need medicine to live their lives. Preventive vaccines are primarily designed for healthy people to protect them from contracting a contagious disease.

The “therapeutic” use of vaccines to treat disease is not within the scope of this discussion.

Because vaccines are given to a healthy population, they normally undergo rigorous safety and efficacy studies in the pre- and post-licensure stages. The safety assessment of a vaccine is supposed to be very strict and thorough before approval.

A drug is prescribed to treat a patient with a medical condition, such as heart disease. A patient may choose to take the drug to improve their symptoms or reduce their risk of death.

The doctor will assess whether the benefits of the drug outweigh the risks of possible side effects. When a patient is suffering from a medical condition, the benefits of a drug often outweigh the risks.

Since a vaccine is administered to a healthy person to protect them from a potential future contagious disease, the risks must be made completely clear. They must be well-informed about the short- and long-term safety and tolerability of a vaccine that has the potential to alter their life by compromising their healthy immune system.

Most importantly, a preventive vaccine should not be associated with or contribute to a death or disability risk known as a “severe adverse event” (SAE).

According to the pharmaceutical industry guidelines from the “International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use,” an SAE, or serious adverse event (experience or reaction), is considered any unexpected medical occurrence that at any dose:

• Results in death.
• Is life-threatening.
• Requires inpatient hospitalization or extension of existing hospitalization.
• Results in persistent or significant disability/incapacity.
• Is a congenital anomaly/birth defect.

Although there is no legal requirement for “zero death tolerance” related to a preventive vaccine, continuing to administer the vaccine when death appears to be associated, clearly violates the Hippocratic oath.

In April 2016, the Philippines began a dengue disease vaccination (Dengvaxia) program for 9-year-old children. The program involved around 875,000 children each given at least one dose; around 400,000 with two doses; and 350,000 receiving all three doses.

As of September 2018, 19 deaths of children were confirmed to be linked with the vaccination. In February 2019, the license was revoked in the Philippines.

A prominent pediatrician and medical researcher in the Philippines was indicted over the failed introduction of Dengvaxia.

After thorough research on the safety of the HPV vaccine and based on my causal analysis, there have been reported SAEs, including deaths, that are associated with the HPV vaccine.

This is very disturbing and not getting enough coverage. Why?

Deaths of Healthy Girls After HPV Vaccine, Reported by FDA and CDC

During my career, I have also worked in the field of medical safety for pharmaceutical companies. My role was to determine whether a causal relationship existed between a particular drug with an SAE. I have thoroughly evaluated hundreds of cases with serious adverse events.

Based on my work in this area, I am confident to attribute the causal assessment of the following events to the HPV vaccine. An assessment of risks is essential to making an informed decision about whether to take the HPV vaccine.

A comprehensive analysis was conducted based on SAEs reported to the Vaccine Adverse Event Reporting System associated with the administration of qHPV vaccine, Gardasil, in females aged 9 to 26 years. The study was published in the top-rank medical journal JAMA and it is authored by the FDA and CDC.

Within only two years of the Gardasil vaccine availability, there were 32 deaths with a mean age of 18. The median time to death was 14.5 days, and the mean time to death was 47 days. Among these 32 death cases, six were cardiac-related (four arrhythmias and two cases of myocarditis), and three were related to pulmonary embolism.

Please note, when dealing with a dataset for which “a normal distribution” has not been validated, we must use the median instead of the mean. This is because the median is more representative of the overall trend within an unidentified data group.

It’s crucial to emphasize that this group of young, healthy girls, with relatively clean medical backgrounds, free of preexisting health conditions to attribute to their death, died within a median time of 14.5 days following qHPV vaccination.

Based on the standard industry criteria (pdf) for the assessment of causality of a drug with an adverse event, these death events had a plausible time relationship to the vaccine administration, and they cannot be explained by other preexisting medical conditions in these young girls.

The causal relationship with the HPV vaccine, if not highly likely, should be considered as at least “probable/likely/plausible” and not excluded.

If I were to regard these deaths as “not related,” it would be an irresponsible judgment on my part and a violation of my oath as a medical doctor.

Others may argue that these deaths are unrelated, with no evidence recognizing an association with the HPV vaccine.

However, just because a causal relationship hasn’t been fully recognized doesn’t mean that a relationship is nonexistent.

The analysis concluded that the deaths did not meet the screening criteria for signal detection, which is typically based on finding a pattern from more than a single report to justify the need for further assessment in determining a causal relationship. However, this is not merely a matter of statistics. Every single case of death deserves a thorough investigation into the possible causal relationship after a medical intervention such as the HPV vaccine.

Cochrane Review Reported Higher Death Rates in HPV Vaccine Group

A Cochrane review (pdf) reported more deaths in the HPV vaccine groups than in the comparator groups. The death rate was significantly increased by 2.36 times in women older than 25 years of age.

This data was hidden in the “Table Summary of Findings 3” on page 10. Page 36 states, “When all the deaths among mid-adult women enrolled in the three trials are pooled, a higher case fatality rate was observed among those who received HPV vaccine compared to those who received placebo.”

The report also stated, “The higher number of deaths in the vaccine arms among mid-adult women may be a chance occurrence since there was no pattern either in the causes of death, or in the timing of the occurrence of death (the period between vaccine administration and date of death). In the study reports, none of the deaths were deemed to be related to vaccination.”

From a standard safety analysis, in each study, every death case has to provide a thorough narrative regarding the causality analysis of the role of the HPV vaccine. Age, gender, time from vaccination to death, and the cause of death, must be provided in detail.

Unfortunately, there is no such detailed narrative in this review, and only a few tables with simple information are listed.

The causality of these death cases remains questionable. Further due diligence is warranted and an investigation on the cause of death should be conducted.

Deaths Due to Fatal Autoimmune Vasculitis

Autoimmune vasculitis is an autoimmune-related inflammation of a blood vessel caused when the body’s immune system attacks a blood vessel by mistake.

In 2012, a peer-reviewed research article published in Pharmaceutical Regulatory Affairs: Open Access reported research on two deaths after HPV vaccination (pdf).

The research was conducted to determine if serious autoimmune and neurological adverse drug reactions following HPV vaccination were causal or merely coincidental and to validate the protocol used for assessing causality in the vaccination-suspected serious adverse neurological outcomes.

Post-mortem brain tissue specimens from two young women who suffered from cerebral vasculitis-type symptoms following vaccination with Gardasil were analyzed by immunohistochemical (IHC) for various immunoinflammatory markers.

IHC is a way to stain targeted substances, such as proteins, at a microscopic level by using the principle of antigen and antibody binding (“immuno-“) within the tissues (“histo-“) and then using a coloring method (“chemical”) to make the tissue visible under the microscope.

In the following cases, the HPV viral protein was stained for identification. Brain sections were also stained for antibodies recognizing HPV-16L1 and HPV-18L1 antigens, which are present in the Gardasil vaccine.

This is taken from a long document. Read the rest here theepochtimes

Please Donate Below To Support Our Ongoing Work To Defend The Scientific Method

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.